search

All clinical trials

Results 460271-460280 of 470744

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

Alzheimer Disease

This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for participation in an ongoing clinical trial. Eligible participants must have previously completed participation in a clinical trial of TRx0237 conducted by TauRx or have previously taken TRx0237 in a compassionate use program, among other criteria. Patients will be considered where a physician can demonstrate clinical benefit for a patient not meeting these criteria; in these cases, TauRx will consider participation of the patient on a case-by-case basis.

Available17 enrollment criteria

Expanded Access Program for Patients With Migraine

Migraine

This expanded access program is designed to make fremanezumab available to patients with EM or CM who have successfully completed (per protocol) Teva-sponsored Study TV48125-CNS-30051 or TV48125-CNS-30068 ("prior studies") until fremanezumab becomes commercially available in their country.

No longer available11 enrollment criteria

An Intermediate Expanded Use Trial of DFMO

NeuroblastomaMedulloblastoma4 more

To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.

Available13 enrollment criteria

Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency...

HIV Infections

Compassionate use access to fostemsavir (GSK3684934, formerly BMS-663068) for the treatment of HIV infection in individuals with multidrug resistant HIV-1 infection who are experiencing virologic failure and are unable to comprise a suppressive regimen with currently available antiretrovirals. Direct inquires to the ViiV Compassionate Use Portal via https://viiv-cu-portal.idea-point.com/

Available19 enrollment criteria

Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum...

Postpartum Depression

This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial availability. Requests for access must be made by a healthcare provider for a specific patient based on a determination with patient that the benefits of treatment outweigh the risks and an assessment of eligibility based on program criteria. Sites with eligible patients must apply and meet requirements for participation in the expanded access program.

Approved for marketing8 enrollment criteria

Expanded Access to NanoPac

NanOlogy may consider offering expanded access to NanoPac for patients who do not meet the enrollment criteria of clinical trials in progress.

Available2 enrollment criteria

ZX008 Expanded Access Protocol

Dravet Syndrome

The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 clinical trials.

Approved for marketing9 enrollment criteria

Expanded Access to Burosumab

X-linked HypophosphatemiaTumor-Induced Osteomalacia

Individual patient expanded access requests may be considered for patients who have no other treatment options

Available2 enrollment criteria

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer...

Recurrent Bladder Cancer

This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer

No longer available3 enrollment criteria

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative...

Lung DiseasesInterstitial

This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.

Approved for marketing2 enrollment criteria
1...460274602846029...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs